VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (bsADC) program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb. The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an “AND-gate” approach intended to improve precision in treating solid tumors.
Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize products arising from the collaboration, with OmniAb entitled to a share of specified revenue generated from resulting products. The full press release is available at https://ibn.fm/qMRuJ.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
The advancement of VXA-222 underscores the potential of bispecific ADCs to enhance tumor targeting and reduce off-target effects, addressing a significant challenge in oncology. By leveraging OmniAb’s discovery capabilities alongside its own linker and conjugation expertise, VERAXA is positioning itself to develop more precise therapies for solid tumors. The “AND-gate” logic of VXA-222 aims to ensure that the drug is activated only when both target antigens are present, which could lead to improved safety and efficacy profiles compared to traditional ADCs.
This milestone is important for VERAXA as it validates the collaboration’s progress and moves the program closer to preclinical and clinical evaluation. The company’s focus on innovative antibody formats, including BiTAC, a registered trademark of VERAXA Biotech GmbH, highlights its commitment to advancing cancer treatment options. Investors and stakeholders can find the latest news and updates relating to VRXA in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s SEC filings. The original release is available on www.newmediawire.com.
